Formal Japanese approval for Erbitux
This article was originally published in Scrip
ImClone Systems/Merck KGaA's EGFR-targeting antibody Erbitux (cetuximab) has received formal final approval from Japan's ministry of health, labour and welfare, for the treatment of inoperable, advanced or recurrent metastatic colorectal cancer.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.